Journal
RESEARCH
Volume 2022, Issue -, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.34133/2022/9768687
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [31930067, 31800797, 31771096, 81860543, 31525009]
- National Key Research and Development Program of China [2017YFC1103502]
- 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYGD18002]
Ask authors/readers for more resources
This study combines chemotherapy with protein tyrosine phosphatase nonreceptor type 2 (Ptpn2)-based immunotherapy to improve the efficacy of melanoma treatment. The prepared nanoparticles effectively evade the reticuloendothelial system and accumulate in tumor sites. The multifunctional nanoparticles directly kill tumor cells, stimulate immunogenic cell death, and promote immune cell activation.
Improving the efficacy of melanoma treatment remains an important global challenge. Here, we combined chemotherapy with protein tyrosine phosphatase nonreceptor type 2(Ptpn2) based immunotherapy in an effort to address this challenge. Short-hairpin RNA (shRNA) targeting Ptpn2 was coencapsulated with doxorubicin (DOX) in the cell membrane of M1 macrophages (M1HD@RPR). The prepared nanoparticles (NPs) were effectively phagocytosed by B16F10 cells and M1 macrophages, but not by M0 macrophages. Hence, NP evasion from the reticuloendothelial system (RES) was improved and NP enrichment in tumor sites increased. M1HD@RPR can directly kill tumor cells and stimulate immunogenic cell death (ICD) by DOX and downregulate Ptpn2. It can promote M1 macrophage polarization and dendritic cell maturation and increase the proportion of CD8(+) T cells. M1HD@RPR killed and inhibited the growth of primary melanoma and lung metastatic tumor cells without harming the surrounding tissue. These findings establish M1HD@RPR as a safe multifunctional nanoparticle capable of effectively combining chemotherapy and gene immunotherapies against melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available